

**Proposed Substitute
Bill No. 28**

LCO No. 5204

**AN ACT REQUIRING PHARMACISTS TO INCLUDE MANUFACTURER
NAMES AND MEDWATCH REPORTING INFORMATION ON GENERIC
DRUG CONTAINERS.**

Be it enacted by the Senate and House of Representatives in General Assembly convened:

1 Section 1. Section 20-617 of the general statutes is repealed and the
2 following is substituted in lieu thereof (*Effective January 1, 2016*):

3 (a) Each pharmacist shall include on the label of each prescription
4 container: (1) The quantity of prescribed drug placed in such container,
5 in addition to any other information required by law, [;] and (2) a
6 prominently printed expiration date based on the manufacturer's
7 recommended conditions of use and storage that can be read and
8 understood by the ordinary individual. The expiration date required
9 pursuant to subdivision (2) of this [section] subsection shall be no later
10 than the expiration date determined by the manufacturer.

11 (b) In addition to the information required to be included on the
12 label of each prescription container pursuant to subsection (a) of this
13 section, each pharmacist shall include on the label of each prescription
14 container for a drug sold only by generic name, as defined in section
15 20-14a, and not by brand name, as defined in said section: (1) The
16 name of the manufacturer of the generic drug placed in the container,
17 and (2) the Internet web site and toll-free telephone number for the

18 United States Food and Drug Administration's safety information and
19 adverse event reporting program (MedWatch).

20 Sec. 2. Section 21a-317 of the general statutes is repealed and the
21 following is substituted in lieu thereof (*Effective October 1, 2015*):

22 (a) Every practitioner who distributes, administers or dispenses any
23 controlled substance or who proposes to engage in distributing,
24 prescribing, administering or dispensing any controlled substance
25 within this state shall (1) obtain a certificate of registration issued by
26 the Commissioner of Consumer Protection in accordance with the
27 provisions of this chapter, and (2) register for access to the electronic
28 prescription drug monitoring program established pursuant to
29 subsection (j) of section 21a-254. Registration for access to said
30 program shall be in a manner prescribed by said commissioner.

31 (b) The commissioner shall not issue or renew a license of a
32 practitioner who distributes, administers or dispenses any controlled
33 substance or who proposes to engage in distributing, prescribing,
34 administering or dispensing any controlled substance within this state
35 unless such practitioner has obtained a certificate of registration and
36 registered for access to the electronic prescription drug monitoring
37 program established pursuant to subsection (j) of section 21a-254.

38 Sec. 3. (NEW) (*Effective October 1, 2015*) (a) As used in this section:

39 (1) "Complex or chronic medical condition" means a physical,
40 behavioral or developmental condition that has been diagnosed or is
41 being treated by a prescribing practitioner and: (A) Has no known
42 cure, (B) is progressive, or (C) can be debilitating or fatal if left
43 untreated or undertreated.

44 (2) "Rare medical condition" means a disease or condition that has
45 been diagnosed or is being treated by a prescribing practitioner and
46 that affects fewer than either: (A) Two hundred thousand persons in
47 the United States, or (B) less than or equal to one out of one thousand
48 five hundred persons worldwide.

49 (3) "Medically stable" means a determination that a patient's
50 condition is not worsening made by a prescribing practitioner, based
51 on the prescribing practitioner's clinical expertise, taking into account
52 the patient's condition and response to treatment.

53 (4) "Drug" has the same meaning as provided in section 20-571 of
54 the general statutes.

55 (5) "Pharmacist" has the same meaning as provided in section 20-571
56 of the general statutes.

57 (6) "Prescribing practitioner" has the same meaning as provided in
58 section 20-571 of the general statutes.

59 (b) If a pharmacist has been informed that a patient is medically
60 stable and diagnosed with a complex or chronic medical condition or a
61 rare medical condition, the pharmacist may not change the drug
62 prescribed to the patient without a medical basis for such change and
63 the express written consent of the prescribing practitioner who
64 prescribed the drug that is subject to the change.

This act shall take effect as follows and shall amend the following sections:		
Section 1	<i>January 1, 2016</i>	20-617
Sec. 2	<i>October 1, 2015</i>	21a-317
Sec. 3	<i>October 1, 2015</i>	New section

Section 1	<i>January 1, 2016</i>	20-617
Sec. 2	<i>October 1, 2015</i>	21a-317
Sec. 3	<i>October 1, 2015</i>	New section